Leap Therapeutics
LPTX
LPTX
43 hedge funds and large institutions have $28.5M invested in Leap Therapeutics in 2023 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 14 increasing their positions, 10 reducing their positions, and 8 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
3.43% less ownership
Funds ownership: 30.28% → 26.85% (-3.4%)
19% less call options, than puts
Call options by funds: $408K | Put options by funds: $503K
Holders
43
Holding in Top 10
–
Calls
$408K
Puts
$503K
Top Buyers
| 1 | +$529K | |
| 2 | +$311K | |
| 3 | +$278K | |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$258K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$250K |
Top Sellers
| 1 | -$1.35M | |
| 2 | -$1M | |
| 3 | -$489K | |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
-$423K |
| 5 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$314K |